Efficacy and safety of bimekizumab in treatment of moderate/severe plaque psoriasis: a systematic review / 药学实践杂志

ABSTRACT

Objective To evaluate the efficacy and safety of bimekizumab in the treatment of moderate/severe plaque psoriasis. Methods Literatures from Cochrane Library, PubMed, Embase, CNKI, VIP databases from the establishment time to January of 2022 were retrieved. The Review manager 5.3 statistical software was used to systematical review. Results 5 publications, 6 RCTs met the inclusion criteria, which involved 2308 participants. In terms of efficacy, patients in the experimental group were more than positive medicine control group in PASI 90, PASI 100, no significantly statistical difference in IGA 0 or 1 cases (P=0.05). PASI 90, PASI 100 and IGA 0 or 1 cases of patients in the experimental group were higher than that of the placebo group . In the safety evaluation, the incidence of adverse reaction in experimental group was higher than the placebo group (P=0.000 2), which was the same as the positive medicine control group (P=0.06). The experimental group was no statistical difference compared with positive medicine control and the placebo group in the incidence of serious adverse events including upper respiratory tract infection and nasopharyngitis (P>0.05). But the rate of oral candidiasis in experimental group was higher than the positive medicine control group (P<0.000 01) and the placebo group (P=0.005). Conclusion bimekizumab could treat moderate/severe plaque psoriasis effectively and safely, and the oral candidiasis during the treatment should be noticed.